D. E. Shaw & Co., Inc. Prothena Corp Public LTD CO Put Options Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $216,894 - $290,265	11,100 New	11,100 $229,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $783,246 - $1.36 Million	-18,600 Reduced 58.13%	13,400 $662,000
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $674,800 - $1.1 Million	-14,000 Reduced 30.43%	32,000 $2.28 Million
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $401,580 - $632,040	46,000 New	46,000 $474,000

190

42.9M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $661M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.